$IREN NET ASSETS: $5.12 BILLION
MARKET CAP: ~$5.38 BILLION
Let that sink in.
The market is valuing IREN at barely 1.05x its reported shareholders’ equity.
A company building a massive AI infrastructure platform, with billions invested in data centers, power infrastructure and GPU capacity, is trading at a valuation remarkably close to its net book value.
The market is pricing in an extraordinary amount of pessimism.
The disconnect between IREN’s underlying asset base and its long-term AI infrastructure potential is becoming increasingly difficult to ignore.
YankeesCaptain retweeted
$IREN JUST HIT 1 PRICE TO BOOK VALUE
YankeesCaptain retweeted
$IREN
$5.73B in cash.
$6B worth of physical buildings and land completely debt-free.
Current market cap: $5.33B.
Accurate as fk
If you buy before the weekend, Trump will invade Iran after the market closes today.
If you don't buy, $QQQ will gap up 6% on Monday.
2
33
YankeesCaptain retweeted
Market Forecast:
Black Monday
Black Tuesday
Black Wednesday
Black Thursday
Black Friday
YankeesCaptain retweeted
NASDAQ 100 POSTS ONE OF ITS MOST EXTREME INTRADAY REVERSALS SINCE 2009
The Nasdaq 100 swung from a gain of more than 2% to a loss of over 2% on Thursday, a reversal seen only three other times since 2009, according to Bloomberg.
🔸 Nasdaq 100: Down more than 15% from its October peak.
🔸 Previous reversals: March 2020, July 2020 and November 2025.
🔸 Historical performance: Median gain of 4.2% over the following five sessions after roughly 30 comparable reversals since 1985.
The selloff reflects AI valuation concerns, hawkish Fed signals and investor deleveraging.
Historically, such extreme reversals have sometimes preceded market rebounds, though further downside remains possible.
Well.. whats the catalyst now that breaks these dooms day for tech stocks? #StockMarket $NDAQ
26
just when I thought yesterday was ridiculous, then next day happens... I guess I keep saying the same think over and over. May not be the .com bust but surely feels like it. brutal.
21
YankeesCaptain retweeted
$VKTX Jefferies BUY PT $101 Bottom line. continue to see VK2735 as one of the most differentiated late-stage obesity assets, pairing potentially competitive weight loss and good tolerability with an increasingly compelling maintenance story.
$VKTX @jefferies only matter time before we see 2735/3019 combo. Also mentioned 3019 multiple back up compounds with even longer half life’s
$VKTX 💪💪
$VKTX BRiley PT$85 Viking’s amylin VK3019 posted 12.0% weight loss in 19 days of monkey dosing, nearly triple what its own lead drug VK2735 managed,
and more than Lilly’s tirzepatide delivered in eight weeks.
• Two backup molecules last twice as long, putting a once-monthly combination shot in play.
• VK2735’s cholesterol and triglyceride gains survived the step down from weekly to monthly dosing.
• First human VK3019 data hits in 4Q26, and at ~$2.4B EV, the market is paying almost nothing for the amylin franchise
1
201

















